Prognostic Value off Bronchoalveolar Lavage Lymphocyte Count in Recently Diagnosed Pulmonary Sarcoidosis (8)
On the other hand, 36 subjects out of the 80 not requiring treatment at the first visit (45 percent) had a lymphocyte count ^30 percent; the difference in the mean proportion of high-intensity alveolitis between these two groups was not significant (p=0.087). antibiotics levaquin
To evaluate the prognostic value of the initial BAL lymphocyte count, we excluded the 20 patients who were treated before six months of follow-up. Of the remaining patients, the 44 subjects with a high-intensity alveolitis (2:30 percent lymphocytes) at diagnosis were compared with the 34 with a lower BAL lymphocyte count (<30 percent). Pulmonary function test results obtained at their last follow-up visit or before treatment were used as the evaluation criteria. In both groups, the mean duration of follow-up was 23.1 months. To ensure the comparability of the mean pulmonary function measurements in the two groups, all the analyses were adjusted for the duration of follow-up and for the pulmonary function values at the time of diagnosis. Pulmonary function values were not different for subjects with high- or low^intensity alveolitis at diagnosis (Fig 1, A). Similar results were obtained when only subjects with biopsy-proven sarcoidosis were analyzed (Fig 1, B). Further analysis grouping subjects into three categories according to their percentage lymphocyte count (<30, 30 to 39, ^40 percent) instead of two showed no trend in any of these parameters (data not shown).
Figure 1. Mean pulmonary (unction measured at the end of follow-up for patients who had a follow-up of at least six months without treatment. A, All patients. B, Patients with biopsy-proven sarcoidosis. Subjects were grouped according to the BAL lymphocyte count at diagnosis (<30 percent, solid bars; ^30 percent, hatched bars). The means (SEM) are adjusted for the pulmonary function values obtained at diagnosis and the follow-up duration. No significant difference could be seen in these parameters between the subgroups of patients.